Crispr Therapeutics (CH:1CG)
NASDAQ:1CG
Total Valuation
Crispr Therapeutics AG has a market cap or net worth of CHF4.29B. The enterprise value is $5.48B.
Market CapCHF4.29B
Enterprise Value$5.48B
Share Statistics
Crispr Therapeutics AG has 96,448,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96,448,790
Owned by Insiders2.54%
Owned by Institutions43.95%
Financial Efficiency
Crispr Therapeutics AG’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -26.62%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-26.62%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee8.93K
Profits Per Employee-1.48M
Employee Count393
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crispr Therapeutics AG is ―. Crispr Therapeutics AG’s PEG ratio is -0.17.
PE Ratio―
PS Ratio1343.50
PB Ratio2.45
Price to Fair Value2.45
Price to FCF-13.63
Price to Operating Cash Flow-13.19
PEG Ratio-0.17
Income Statement
In the last 12 months, Crispr Therapeutics AG had revenue of 3.51M and earned -581.60M in profits. Earnings per share was -6.47.
Revenue3.51M
Gross Profit-229.45M
Operating Income-568.32M
Pretax Income-577.97M
Net Income-581.60M
EBITDA-558.49M
Earnings Per Share (EPS)-6.47
Cash Flow
In the last 12 months, operating cash flow was -399.96M and capital expenditures -1.21M, giving a free cash flow of -401.18M billion.
Operating Cash Flow-399.96M
Free Cash Flow-401.18M
Free Cash Flow per Share-4.16
Dividends & Yields
Crispr Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Crispr Therapeutics AG upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Crispr Therapeutics AG as a current ratio of 13.32, with Debt / Equity ratio of 43.41%
Current Ratio13.32
Quick Ratio13.32
Debt to Market Cap0.04
Net Debt to EBITDA-0.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Crispr Therapeutics AG has paid 3.63M in taxes.
Income Tax3.63M
Effective Tax Rate>-0.01
Enterprise Valuation
Crispr Therapeutics AG EV to EBITDA ratio is -8.51, with an EV/FCF ratio of -13.75.
EV to Sales1.35K
EV to EBITDA-8.51
EV to Free Cash Flow-13.75
EV to Operating Cash Flow-13.78
Balance Sheet
Crispr Therapeutics AG has CHF2.44B in cash and marketable securities with CHF787.64M in debt, giving a net cash position of CHF1.65B billion.
Cash & Marketable SecuritiesCHF2.44B
Total DebtCHF787.64M
Net CashCHF1.65B
Net Cash Per ShareCHF17.15
Tangible Book Value Per ShareCHF21.37
Margins
Gross margin is -5360.86%, with operating margin of -16191.40%, and net profit margin of -16569.77%.
Gross Margin-5360.86%
Operating Margin-16191.40%
Pretax Margin-16466.24%
Net Profit Margin-16569.77%
EBITDA Margin-15911.28%
EBIT Margin-16466.24%
Analyst Forecast
The average price target for Crispr Therapeutics AG is CHF59.81, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF59.81
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count14
Revenue Growth Forecast-90.08%
EPS Growth Forecast-24.51%